Concluding a trilogy started in 2014, Maze Runner: The Death Cure races into theaters next Friday. Based on the James Dashner series of YA books, the sci-fi action pic stars Dylan O’Brien, Kaya Scodelario, Thomas Brodie-Sangster, Will Poulter, Nathalie Emmanuel, Giancarlo Esposito, Walton Goggins, Barry Pepper, and Patricia Clarkson. Wes Ball, who directed the first two installments, returns behind the camera. Reviews are so so thus far with a 40% Rotten Tomatoes score.
The reported $83 million production was originally scheduled for release in February 2017 until an injury suffered by star O’Brien on the set delayed production. The nearly two and a half-year lag time between sequels could be a hindrance to its potential.
In September 2014, the original Runner opened to $32 million with an eventual $102 million domestic haul. Sequel The Scorch Trials arrived one year later to diminishing returns – a $30 million debut and $81 million overall take. Enough of the fan base may stick around, but I wouldn’t be surprised to see Death take in about 25% less out of the gate than its predecessor in 2015.
Maze Runner: The Death Cure opening weekend prediction: $22.8 million
All My Life... I Wanted To Be A Blogster 